Aurobindo Pharma gains 15% as USFDA grants VAI to Unit IV facility

The facility remains important as it contributes more than 10 per cent to Aurobindo's overall sales and about 20 per cent of the US sales

Shares of Aurobindo Pharma surged 15 per cent to Rs 621.60 on the BSE in an otherwise weak market on Tuesday after US drug regulator USFDA classified the company's Unit IV of Hyderabad plant as VAI (voluntary action indicated).

At 10:00 am, the stock was trading 12 per cent higher at Rs 605, as compared to 2.6 per cent decline in the benchmark S&P BSE Sensex. A combined 6.8 million shares have changed hands on the counter on the NSE and BSE. The pharma stock is trading on future & option (F&O) segment, which has no circuit limits. The